Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

4354 - Knowledge and perception of clinical trials (CTs) and attitude towards participation among Polish oncological patients - A pilot survey


30 Sep 2019


Poster Display session 3


Bioethical Principles and GCP

Tumour Site


Artur Kotowski


Annals of Oncology (2019) 30 (suppl_5): v671-v682. 10.1093/annonc/mdz263


A. Kotowski1, D. Świetlik2, M. Kotowska3, M. Wronowski4, A.M. Fal5

Author affiliations

  • 1 Gcppl, Polish Association for Good Clinical Practice, 02-106 - Warsaw/PL
  • 2 Intrafaculty College Of Medical Informatics And Biostatistics, Medical University of Gdańsk, 80-210 - Gdańsk/PL
  • 3 Ii Faculty Of Medicine, Medical University of Warsaw, 02-091 - Warsaw/PL
  • 4 Infectious Diseases, Medical University of Warsaw, 02-091 - Warsaw/PL
  • 5 Uksw, Cardinal Stefan Wyszyński University, 01-815 - Warsaw/PL


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4354


Patients’ perception of clinical trials in Poland is mostly influenced by mass media. The image of CTs is often biased which may have an impact on recruitment.


Based on an anonymous 25-item Paper and Pencil Interview (PAPI) survey among 191 hospitalized oncological patients we analyzed knowledge, perception, willingness to participate and future expectations of CTs. Nominal scale: Yes/No/Don’t know, Likert scale of 0-5 points and multiple choice questions were applied.


The majority of respondents were: (1) women: 70,2%, (2) people with secondary education: 57,6%, (3) at the age of 60-69: 41,9%, (4) living in cities over 100k inhabitants: 46,1%. Main findings 49,2% of respondents agreed to be enrolled in CTs; 15,3% refused and 35,4% were not certain. Among the driving factors for “YES” were: chance for a better/constant care - 76,3% and access to additional monitoring - 73,1%. 57,0% of respondents declared altruistic reason. The main reasons for not participating were: concern about toxicity - 62,1%, lack of efficacy - 55,2% and being a “guinea pig” - 41,4%. Among respondents uncertain about participation in CT, the factors of the highest impact on potential enrollment were: terminal phase of the disease/no other option: 68,7%/ 56,7%. The incentive of the family member or friend does not have a significant impact - only 19,4% respondents would follow it. Other findings 55,8%/ 54,7% of respondents do not know about the existence of any legal acts/state institutions that oversee CTs. 60,8% of respondents do not know whether there are independent bioethical committees that approve each CT prior to launch. 64,9% of respondents think that research funded by pharma companies is NOT as reliable as that of independent sources eg. medical universities. 76,2% of respondents think that the current amount of information on CTs is insufficient and 87,2% would like to know more.


The level of knowledge about CTs among patients is insufficient but the willingness to participate is high which is mainly driven by a possibility of a better and constant care. The trust in the pharmaceutical industry should be increased.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


A. Kotowski: Full / Part-time employment: Roche Polska sp z o.o. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.